References
- Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12
- NICE. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal guidance 118). London, 2012. http://www.nice.org.uk/guidance/ta242. Accessed May 24, 2013
- Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010;28:3687-94
- Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010;103:324-31
- Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012;35:1066-73
- Bester L, Meteling B, Pocock N, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012;23:96-105
- NICE. Guide to the methods of technology appraisal. London, 2013. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf. Accessed May 24, 2013
- Hoyle M, Crathorne L, Peters P, et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess 2013;17:1-237
- Akaike H. A new look at the statistical model identification. IEEE Trans Auto Contr 1974;19:716-23
- The Christie NHS Foundation Trust. SIRT equipment costs. Manchester, 2012
- NHS. National schedule of reference costs 2010–2011. London, 2012. https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012. Accessed June 12, 2013
- NICE. Colorectal Cancer: the diagnosis and management of colorectal cancer. London, 2011. http://www.nice.org.uk/guidance/cg131/resources/guidance-colorectal-cancer-pdf. Accessed May 24, 2013
- Addicott R, Dewar S. Improving choice at end of life: a descriptive analysis of the impact and costs of the Marie Curie Delivering Choice Programme in Lincolnshire. London: The King's Fund, 2008. http://www.kingsfund.org.uk/sites/files/kf/improving-choice-end-of-life-descriptive-analysis-impact-costs-marie-curie-choice-programme-lincolnshire-rachael-addicot-steve-dewar-april-2008.pdf. Accessed June 12, 2013
- NICE. Erlotinib for the treatment of relapsed non-small cell lung cancer: ERG report. London, 2006. Available at: http://www.nice.org.uk/guidance/ta162/resources/lung-cancer-nonsmallcell-erlotinib-evidence-review-group-report2. Accessed June 12, 2013
- NICE. Trastuzumab for the treatment of HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction: ERG report. London, 2010. Available at: http://www.hta.ac.uk/erg/reports/2234.pdf. Accessed June 12, 2013
- Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press, 2012. Available at: http://www.bnf.org/bnf/index.htm Accessed June 12, 2013
- Ramsey S, Andersen M, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88(6):1294-303